Apozeal Pharmaceuticals Inc
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- United States
- Registered address
- 2091 Hartel St, Levittown, Pennsylvania (PA) 19057, United States (USA)
- Operations here
- analysismanufacturepackrelabelrepack
- FDA identifiers
- FEI 3004536846 · DUNS 119101193
Recent inspection flagged official action
FDA classified an inspection here as OAI (official action indicated) within the last two years — the strongest public warning signal a facility gets. This plant is listed on labels for 3 drugs. A supply problem here can ripple to all of them.
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- OAIDrug Quality Assurance2025-10-15
- NAIDrug Quality Assurance2021-12-15
- OAIDrug Quality Assurance2019-04-09
- NAIDrug Quality Assurance2018-11-09
- NAIDrug Quality Assurance2017-04-05
- VAIDrug Quality Assurance2012-11-21
- VAIDrug Quality Assurance2009-10-27
Drugs this plant is listed as making
3 distinct drugs across 3 products name this site in their FDA label.
- Aminocaproic AcidApozeal Pharmaceuticals Inc.
- Cetirizine Hydrochloride Oral SolutionApozeal Pharmaceuticals Inc
- LactuloseApozeal Pharmaceuticals Inc
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.